U3 Shut Down As Daiichi Sankyo Streamlines R&D
This article was originally published in PharmAsia News
Executive Summary
Some seven and a half years after buying the venture, Daiichi Sankyo is shutting down its German oncology biologics research operation U3 Pharma, although its remaining pipeline assets are being retained internally.
You may also be interested in...
Daiichi Closing Indian Site As Global Restructuring Continues
Daiichi Sankyo's decision to close an R&D facility in India has drawn mixed responses from the local industry, coming as it does against the backdrop of the Japanese firm’s disastrous acquisition of Ranbaxy.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: the shifting sands of pharma R&D; big pharma oncology strategies; semaglutide’s promise in heart failure; AstraZeneca looks to multiple cancer modalities; and an interview with Astellas’s chief strategy officer.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: Genmab buys into ADCs; Roivant set to take on AbbVie in uveitis; Ipsen signs firs ADC pact; South Korea looks to build biotech momentum; and the end of the road for Acorda.